Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

Abstract

The prevention of atherothrombotic events is the primary goal in the treatment of patients with arteriosclerotic disorders. Despite recent improvements in the management of coronary artery disease (CAD) with revascularization techniques and antiplatelet therapy, some patients remain at risk of recurrent cardiovascular events. This could be related to additional thrombin generation. As a result, there has been interest in developing novel therapies to prevent thromboembolic events, targeting thrombin-mediated pathways. These include non–vitamin K antagonist oral anticoagulants (NOACs). This article aims to summarize the recent clinical studies that investigated the role of NOACs in CAD.

Haemostaseological pearls

“…Several studies have investigated the role of different DOACs in the treatment of patients with acute or chronic coronary artery disease, and with atrial fibrillation undergoing percutaneous coronary intervention. The review by Al Said et al 8 provides an excellent comprehensive summary of these most recent clinical studies that is worth reading.…”

Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling

“…These pitfalls have fueled the quest for safer alternatives [13]. This pursuit culminated in the emergence of Non-Vitamin K Oral Anticoagulants (NOACs), also known as Direct Oral Anticoagulants (DOACs), fundamentally transforming the anticoagulation landscape [14].…”